Sodium channel antagonists for the treatment of migraine

Bibliography

• Lipton RB, Bigal ME, Diamond M, Freitag F, et al. AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68(5):343-9
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The international classification of headeache disorders, 3rd edition (beta version). Cephalalgia 2013;33(9):629-808
   PubMed Web of Science ®Google Scholar
• Moskowitz MA. Genes, proteases, cortical spreading depression and migraine: impact on pathophysiology and treatment. Funct Neurol 2007;22(3):133-6
   PubMedGoogle Scholar
• Arulmozhi DK, Veeranjaneyulu A, Bodhankar SL. Migraine: current concepts and emerging therapies. Vascul Pharmacol 2005;43(3):176-87
   PubMedGoogle Scholar
• Schwedt TJ, Dodick DW. Advanced neuroimaging of migraine. Lancet Neurol 2009;8(6):560-8
   PubMed Web of Science ®Google Scholar
• Pietrobon D. Function and dysfunction of synaptic calcium channels: insights from mouse models. Curr Opin Neurobiol 2005;15(3):257-65
   PubMedGoogle Scholar
• Wessman M, Terwindt GM, Kaunisto MA, et al. Migraine: a complex genetic disorder. Lancet Neurol 2007;6(6):521-32
   PubMed Web of Science ®Google Scholar
• Russell MB. Is migraine a genetic illness? The various forms of migraine share a common genetic cause. Neurol Sci 2008;29(Suppl 1):S52-4
   PubMedGoogle Scholar
• Mantegazza M, Curia G, Biagini G, et al. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 2010;9(4):413-24
   PubMed Web of Science ®Google Scholar
• Buzzi MG, Moskowitz MA. The pathophysiology of migraine: year 2005. J Headache Pain 2005;6(3):105-11
   PubMedGoogle Scholar
• Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 2003;4(5):386-98
   PubMed Web of Science ®Google Scholar
• Pietrobon D. Migraine: new molecular mechanisms. Neuroscientist 2005;11(4):373-86
   PubMedGoogle Scholar
• Dalkara T, Zervas NT, Moskowitz MA. From spreading depression to the trigeminovascular system. Neurol Sci 2006;27(Suppl 2):S86-90
   PubMed Web of Science ®Google Scholar
• Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol 2013;75:365-91
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB, Stewart WF. The epidemiology and impact of migraine. Curr Neurol Neurosci Rep 2004;4(2):98-104
   PubMedGoogle Scholar
• Bonfert M, Straube A, Schroeder AS, et al. Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache. Neuropediatrics 2013;44(1):003-19
   PubMedGoogle Scholar
• Silberstein SD. Preventive treatment of migraine. Trends Pharmacol Sci 2006;27(8):410-15
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD. Migraine prevention. Pract Neurol 2007;7(6):383-93
   PubMedGoogle Scholar
• Calabresi P, Galletti F, Rossi C, et al. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci 2007;28(4):188-95
   PubMed Web of Science ®Google Scholar
• Galletti F, Cupini LM, Corbelli I, et al. Pathophysiological basis of migraine prophylaxis. Prog Neurobiol 2009;89(2):176-92
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Holland S, Freitag F, Dodick DW, et al. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78(17):1337-45
   PubMed Web of Science ®Google Scholar
• Parsekyan D. Migraine prophylaxis in adult patients. West J Med 2000;173(5):341-5
   PubMedGoogle Scholar
• Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem Int 2000;37(2-3):103-10
   PubMed Web of Science ®Google Scholar
• Chapman A, Keane PE, Meldrum BS, et al. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982;19(4):315-59
   PubMedGoogle Scholar
• Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 2012;64(10):887-95
   PubMed Web of Science ®Google Scholar
• Frediani F. Anticonvulsant drugs in primary headaches prophylaxis. Neurol Sci 2004;25(Suppl 3):S161-6
   PubMedGoogle Scholar
• Rodriguez-Sainz A, Pinedo-Brochado A, Sánchez-Menoyo JL, et al. Migraine, stroke and epilepsy: underlying and interrelated causes, diagnosis and treatment. Curr Treat Options Cardiovasc Med 2013;15(3):322-34
   PubMedGoogle Scholar
• Hershey LA, Bednarczyk EM. Treatment of headache in the elderly. Curr Treat Options Neurol 2013;15(1):56-62
   PubMedGoogle Scholar
• Kabbouche MA, Gilman DK. Management of migraine in adolescents. Neuropsychiatr Dis Treat 2008;4(3):535-48
   PubMedGoogle Scholar
• O’Brien HL, Kabbouche MA, Hershey AD. Treating pediatric migraine: an expert opinion. Expert Opin Pharmacother 2012;13(7):959-66
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. Headache 1996;36(9):547-55
   PubMed Web of Science ®Google Scholar
• Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17(2):103-8
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD, Polychronidis I. Valproate versus flunarizine in migraine prophylaxis: a randomized, double-open, clinical trial. Funct Neurol 1997;12(5):267-76
   PubMedGoogle Scholar
• Serdaroglu G, Erhan E, Tekgul H, et al. Sodium valproate prophylaxis in childhood migraine. Headache 2002;42(8):819-22
   PubMedGoogle Scholar
• Apostol G, Pakalnis A, Laforet GA, et al. Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents. Headache 2009;49(1):36-44
   PubMed Web of Science ®Google Scholar
• Apostol G, Lewis DW, Laforet GA, et al. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. Headache 2009;49(1):45-53
   PubMed Web of Science ®Google Scholar
• Toldo I, De Carlo D, Bolzonella B, et al. The pharmacological treatment of migraine in children and adolescents: an overview. Expert Rev Neurother 2012;12(9):1133-42
   PubMed Web of Science ®Google Scholar
• Sørensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand 1988;78(4):346-8
   PubMed Web of Science ®Google Scholar
• Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study. Headache 1991;31(2):71-4
   PubMedGoogle Scholar
• Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992;12(2):81-4
   PubMed Web of Science ®Google Scholar
• Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994;44(4):647-51
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kailasam J, Meadors L, et al. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache 2000;40(9):720-3
   PubMedGoogle Scholar
• Ghose K, Niven B. Prophylactic sodium valproate therapy in patients with drug-resistant migraine. Methods Find Exp Clin Pharmacol 1998;20(4):353-9
   PubMedGoogle Scholar
• Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group. Headache 1999;39(9):633-43
   PubMedGoogle Scholar
• Erdemoglu AK, Ozbakir S. Valproic acid in prophylaxis of refractory migraine. Acta Neurol Scand 2000;102(6):354-8
   PubMedGoogle Scholar
• Freitag FG, Diamond S, Diamond ML, Urban GJ. Divalproex in the long-term treatment of chronic daily headache. Headache 2001;41(3):271-8
   PubMedGoogle Scholar
• Kinze S, Clauss M, Reuter U, et al. Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study. Headache 2001;41(8):774-8
   PubMedGoogle Scholar
• Freitag FG, Collins SD, Carlson HA, Goldstein J, et al. Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58(11):1652-9
   PubMed Web of Science ®Google Scholar
• Shaygannejad V, Janghorbani M, Ghorbani A, et al. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache 2006;46(4):642-8
   PubMedGoogle Scholar
• Yurekli VA, Akhan G, Kutluhan S, et al. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain 2008;9(1):37-41
   PubMedGoogle Scholar
• Afshari D, Rafizadeh S, Rezaei M. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. Int J Neurosci 2012;122(2):60-8
   PubMed Web of Science ®Google Scholar
• Bostani A, Rajabi A, Moradian N, et al. The effects of cinnarizine versus sodium valproate in migraine prophylaxis. Int J Neurosci 2013;123(7):487-93
   PubMed Web of Science ®Google Scholar
• Kozubski W, Prusiński A. Sodium valproate versus propranolol in the prophylactic treatment of migraine. Neurol Neurochir Pol 1995;29(6):937-47
   PubMedGoogle Scholar
• Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997;54(9):1141-5
   PubMedGoogle Scholar
• Kalita J, Bhoi SK, Misra UK. Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial. Acta Neurol Scand 2013;128(1):65-72
   PubMedGoogle Scholar
• Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005;28(6):277-9
   PubMedGoogle Scholar
• Krymchantowski AV, Jevoux CC. Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective “real-world” study. Headache 2011;51(4):554-8
   PubMedGoogle Scholar
• Krymchantowski AV, Jevoux Cda C. Low-dose topiramate plus sodium divalproate for positive responders intolerant to full-dose monotherapy. Headache 2012;52(1):129-32
   PubMedGoogle Scholar
• Norton J. Use of intravenous valproate sodium in status migraine. Headache 2000;40(9):755-7
   PubMed Web of Science ®Google Scholar
• Schwartz TH, Karpitskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache 2002;42(6):519-22
   PubMedGoogle Scholar
• Stillman MJ, Zajac D, Rybicki LA. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. Headache 2004;44(1):65-9
   PubMedGoogle Scholar
• Waberzinek G, Marková J, Mastík J. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine. Neuro Endocrinol Lett 2007;28(1):59-64
   PubMedGoogle Scholar
• Shahien R, Saleh SA, Bowirrat A. Intravenous sodium valproate aborts migraine headaches rapidly. Acta Neurol Scand 2011;123(4):257-65
   PubMedGoogle Scholar
• Foroughipour M, Ghandehari K, Khazaei M, et al. Randomized clinical trial of intravenous valproate (orifil) and dexamethasone in patients with migraine disorder. Iran J Med Sci 2013;38(2 Suppl):150-5
   PubMedGoogle Scholar
• Bakhshayesh B, Seyed Saadat SM, Rezania K, et al. A randomized open-label study of sodium valproate vs sumatriptan and metoclopramide for prolonged migraine headache. Am J Emerg Med 2013;31(3):540-4
   PubMed Web of Science ®Google Scholar
• Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med 2003;41(6):847-53
   PubMed Web of Science ®Google Scholar
• Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache 2001;41(10):976-80
   PubMedGoogle Scholar
• Caruso JM, Brown WD, Exil G, et al. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Headache 2000;40(8):672-6
   PubMedGoogle Scholar
• Pakalnis A, Greenberg G, Drake ME Jr, et al. Pediatric migraine prophylaxis with divalproex. J Child Neurol 2001;16(10):731-4
   PubMedGoogle Scholar
• Hikita T, Kodama H, Nakamoto N, et al. Effective prophylactic therapy for cyclic vomiting syndrome in children using valproate. Brain Dev 2009;31(6):411-13
   PubMedGoogle Scholar
• Apostol G, Cady RK, Laforet GA, et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache 2008;48(7):1012-25
   PubMed Web of Science ®Google Scholar
• Unalp A, Uran N, Oztürk A. Comparison of the effectiveness of topiramate and sodium valproate in pediatric migraine. J Child Neurol 2008;23(12):1377-81
   PubMedGoogle Scholar
• Ashrafi MR, Shabanian R, Zamani GR, et al. Sodium Valproate versus Propranolol in paediatric migraine prophylaxis. Eur J Paediatr Neurol 2005;9(5):333-8
   PubMedGoogle Scholar
• Bidabadi E, Mashouf M. A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients. Paediatr Drugs 2010;12(4):269-75
   PubMedGoogle Scholar
• Reiter PD, Nickisch J, Merritt G. Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Headache 2005;45(7):899-903
   PubMed Web of Science ®Google Scholar
• Costa C, Martella G, Picconi B, et al. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 2006;37(5):1319-26
   PubMed Web of Science ®Google Scholar
• Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 2003;23(18):7069-74
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004;46(8):1097-104
   PubMed Web of Science ®Google Scholar
• White HS, Brown SD, Woodhead JH, et al. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000;41(Suppl 1):S17-20
   PubMed Web of Science ®Google Scholar
• Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001;41(10):968-75
   PubMed Web of Science ®Google Scholar
• Martínez HR, Londoño O, Cantú-Martínez L, et al. Topiramate as an adjunctive treatment in migraine prophylaxis. Headache 2003;43(10):1080-4
   PubMedGoogle Scholar
• Brandes JL, Saper JR, Diamond M, Couch JR, et al. MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291(8):965-73
   PubMed Web of Science ®Google Scholar
• Lewis D, Winner P, Saper J, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics 2009;123(3):924-34
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Neto W, Schmitt J, Jacobs D, et al. MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61(4):490-5
   PubMedGoogle Scholar
• Von Seggern RL, Mannix LK, Adelman JU. Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis. Headache 2002;42(8):804-9
   PubMed Web of Science ®Google Scholar
• Young WB, Hopkins MM, Shechter AL, Silberstein SD. Topiramate: a case series study in migraine prophylaxis. Cephalalgia 2002;22(8):659-63
   PubMed Web of Science ®Google Scholar
• Silvestrini M, Bartolini M, Coccia M, et al. Topiramate in the treatment of chronic migraine. Cephalalgia 2003;23(8):820-4
   PubMedGoogle Scholar
• Mei D, Capuano A, Vollono C, et al. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci 2004;25(5):245-50
   PubMedGoogle Scholar
• Bussone G, Diener HC, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005;59(8):961-8
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Loder E, Forde G, et al. The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin 2006;22(6):1021-9
   PubMed Web of Science ®Google Scholar
• Rapoport A, Mauskop A, Diener HC, et al. Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Headache 2006;46(7):1151-60
   PubMedGoogle Scholar
• Peres MF, Mercante JP, Tanuri FC, et al. Chronic migraine prevention with topiramate. J Headache Pain 2006;7(4):185-7
   PubMedGoogle Scholar
• Mei D, Ferraro D, Zelano G, et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol 2006;29(5):269-75
   PubMedGoogle Scholar
• Silberstein SD, Lipton RB, Dodick DW, Freitag FG, et al. Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007;47(2):170-80
   PubMed Web of Science ®Google Scholar
• Diener HC, Bussone G, Van Oene JC, Lahaye M, et al. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27(7):814-23
   PubMed Web of Science ®Google Scholar
• Artemenko AR, Kurenkov AL, Filatova EG, et al. Effects of topiramate on migraine frequency and cortical excitability in patients with frequent migraine. Cephalalgia 2008;28(3):203-8
   PubMedGoogle Scholar
• Silberstein S, Lipton R, Dodick D, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 2009;49(8):1153-62
   PubMedGoogle Scholar
• Nelles G, Schmitt L, Humbert T, Becker V, et al. TOPMATMIG-0001 investigators. Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting. J Headache Pain 2010;11(1):33-44
   PubMedGoogle Scholar
• Lipton RB, Silberstein S, Dodick D, et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia 2011;31(1):18-30
   PubMedGoogle Scholar
• Silberstein SD, Hulihan J, Karim MR, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther 2006;28(7):1002-11
   PubMed Web of Science ®Google Scholar
• Luo N, Di W, Zhang A, et al. A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Med 2012;13(1):80-6
   PubMed Web of Science ®Google Scholar
• Diener HC, Tfelt-Hansen P, Dahlöf C, et al. MIGR-003 Study Group. Topiramate in migraine prophylaxis – results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251(8):943-50
   PubMed Web of Science ®Google Scholar
• Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 2008;118(5):301-5
   PubMedGoogle Scholar
• Dodick DW, Freitag F, Banks J, Saper J, et al. CAPSS-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009;31(3):542-59
   PubMed Web of Science ®Google Scholar
• Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg 2008;110(10):979-84
   PubMedGoogle Scholar
• Zain S, Khan M, Alam R, et al. Comparison of efficacy and safety of topiramate with gabapentin in migraine prophylaxis: randomized open label control trial. J Pak Med Assoc 2013;63(1):3-7
   PubMedGoogle Scholar
• Gupta P, Singh S, Goyal V, et al. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache 2007;47(3):402-12
   PubMed Web of Science ®Google Scholar
• Hershey AD, Powers SW, Vockell AL, et al. Effectiveness of topiramate in the prevention of childhood headaches. Headache 2002;42(8):810-18
   PubMed Web of Science ®Google Scholar
• Campistol J, Campos J, Casas C, Herranz JL. Topiramate in the prophylactic treatment of migraine in children. J Child Neurol 2005;20(3):251-3
   PubMedGoogle Scholar
• Winner P, Gendolla A, Stayer C, et al. Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety. Headache 2006;46(10):1503-10
   PubMedGoogle Scholar
• Lakshmi CV, Singhi P, Malhi P, Ray M. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. J Child Neurol 2007;22(7):829-35
   PubMed Web of Science ®Google Scholar
• Cruz MJ, Valencia I, Legido A, et al. Efficacy and tolerability of topiramate in pediatric migraine. Pediatr Neurol 2009;41(3):167-70
   PubMed Web of Science ®Google Scholar
• Winner P, Pearlman EM, Linder SL, et al. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 2005;45(10):1304-12
   PubMed Web of Science ®Google Scholar
• Fallah R, Divanizadeh MS, Karimi M, et al. Topiramate and propranolol for prophylaxis of migraine. Indian J Pediatr 2013;80(11):920-4
   PubMedGoogle Scholar
• Kim H, Byun SH, Kim JS, et al. Comparison of flunarizine and topiramate for the prophylaxis of pediatric migraines. Eur J Paediatr Neurol 2013;17(1):45-9
   PubMedGoogle Scholar
• Lampl C, Buzath A, Klinger D, Neumann K. Lamotrigine in the prophylactic treatment of migraine aura – a pilot study. Cephalalgia 1999;19(1):58-63
   PubMed Web of Science ®Google Scholar
• D’Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999;19(1):64-6
   PubMed Web of Science ®Google Scholar
• Pascual J, Caminero AB, Mateos V, et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache 2004;44(10):1024-8
   PubMedGoogle Scholar
• Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005;76(12):1730-2
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997;17(2):109-12
   PubMed Web of Science ®Google Scholar
• Mohammadianinejad SE, Abbasi V, Sajedi SA, et al. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. Clin Neuropharmacol 2011;34(4):174-7
   PubMedGoogle Scholar
• Drake ME Jr, Greathouse NI, Renner JB, Armentbright AD. Open-label zonisamide for refractory migraine. Clin Neuropharmacol 2004;27(6):278-80
   PubMedGoogle Scholar
• Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia 2006;26(10):1199-202
   PubMedGoogle Scholar
• Bermejo PE, Dorado R. Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin Neuropharmacol 2009;32(2):103-6
   PubMedGoogle Scholar
• Pascual-Gómez J, Gracia-Naya M, Leira R, et al. Zonisamide in the preventive treatment of refractory migraine. Rev Neurol 2010;50(3):129-32
   PubMedGoogle Scholar
• Villani V, Ciuffoli A, Prosperini L, Sette G. Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational study. Headache 2011;51(2):287-91
   PubMedGoogle Scholar
• Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbazepine (tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1966;29(3):265-7
   PubMed Web of Science ®Google Scholar
• Rompel H, Bauermeister PW. Aetiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study. S Afr Med J 1970;44(4):75-80
   PubMedGoogle Scholar
• Striano S, Striano P, Di Nocera P, et al. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy. Epilepsy Res 2006;69(2):170-6
   PubMed Web of Science ®Google Scholar
• French JA, Baroldi P, Brittain ST, Johnson JK, et al. PROSPER Investigators Study Group. Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial. Acta Neurol Scand 2014;129(3):143-53
   PubMed Web of Science ®Google Scholar
• Silberstein S, Saper J, Berenson F, et al. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology 2008;70(7):548-55
   PubMedGoogle Scholar
• Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 2012;13(5):361-78
   PubMed Web of Science ®Google Scholar